The Economic Benefits Resulting from the First 8 Years of the Global Programme to Eliminate Lymphatic Filariasis (2000–2007)

BACKGROUND: Between 2000–2007, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) delivered more than 1.9 billion treatments to nearly 600 million individuals via annual mass drug administration (MDA) of anti-filarial drugs (albendazole, ivermectin, diethylcarbamazine) to all at-risk for...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Brian K., Hooper, Pamela J., Bradley, Mark H., McFarland, Deborah A., Ottesen, Eric A.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879371/
https://www.ncbi.nlm.nih.gov/pubmed/20532228
http://dx.doi.org/10.1371/journal.pntd.0000708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879371/
https://www.ncbi.nlm.nih.gov/pubmed/20532228
http://dx.doi.org/10.1371/journal.pntd.0000708

Ejemplares similares